Plegridy (peginterferon beta-1a)
Plegridy® is an interferon beta indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), active secondary progressive MS, and clinically isolated syndrome (CIS). It is a disease-modifying drug (DMD). This form of peginterferon beta-1a is given by injection under the skin (subcutaneous injection) or into the muscle (intramuscular injection). An interferon, it is a group of glycoproteins produced naturally in the body in response to viral infections. Plegridy is intended to slow the build-up of disabilities and reduce the incidence of relapses in people with MS. The active ingredient in Plegridy is peginterferon beta-1a.
How does Plegridy work?
The way Plegridy works is not well understood. It is an interferon, which helps to control immune system activity. It is thought to act by reducing inflammation and the immune response that attacks myelin.
What are the possible side effects of Plegridy?
Many clinical trials evaluated the safety and efficacy of Plegridy. The most common side effects experienced by those taking Plegridy include:
- Flu-like symptoms
- Injection site reactions
- Asthenia (feeling weak or tired)
- Abdominal pain, diarrhea, nausea and vomiting
- Myalgia (muscle or joint pain)
Flu-like symptoms can generally be treated with over-the-counter pain relief medications like acetaminophen or ibuprofen taken before a Plegridy injection.
This is not an exhaustive list of all potential side effects of Plegridy. For more information, consult your doctor or healthcare provider. If you notice any new or worsening side effects when taking Plegridy, contact your doctor or healthcare provider immediately.
Things to note about Plegridy
Plegridy should be stored in the refrigerator in its original carton and protected from light. Once removed from the refrigerator, it should be allowed to warm to room temperature (about 30 minutes) prior to injection.
Before starting Plegridy, talk with your doctor if you:
- Have a history of hypersensitivity to natural or recombinant interferon beta or peginterferon, or any other component of the formulation
- Have hepatic (liver) injury
- Have a history of depression or suicidal ideation. Any new symptoms of depression, suicidal ideation, and/or psychosis should be reported immediately to your doctor.
- Have a history of seizures
- Have a history of anaphylaxis
- Are a congestive heart failure patient, who should be monitored for worsening symptoms
- Are pregnant or planning to get pregnant, as there is limited information on the use of Plegridy in pregnancy. It should be used only if the potential benefit of Plegridy therapy exceeds risk to the fetus.
- Have Thrombotic Microangiopathy (damage to small blood vessels in vital organs)
- Experience development of new autoimmune disorders
Individuals with the above conditions should be monitored closely while taking Plegridy.